A Multicenter, Phase II, Randomized, Open Label Trial of 2 Dose Levels of RTA 402 [CDDO-Me] in Patients With Advanced Malignant Melanoma
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 02 Dec 2014
At a glance
- Drugs Bardoxolone methyl (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Reata Pharmaceuticals
- 10 Dec 2007 Status changed from initiated to withdrawn prior to recruitment. This study was withdrawn prior to recruitment.
- 05 Nov 2007 New trial record.